Built on an improved macroporous agarose-based matrix and coupled with an alkali-stable recombinant Protein A ligand, WorkBeads affimAb Edge delivers:

• High performance and process economy: Dynamic binding capacities exceeding 70 mg/mL at 6 minutes residence time.
• Superior pressure flow properties: Enabling faster cycle times and robust process scalability.
• Alkali stability: Supporting repeated cleaning and sanitization with 0.5 M NaOH for extended resin lifetime.
• Improved purity: Demonstrated effective removal of host cell proteins (HCP) with consistently low impurity levels across 150+ cycles.
• Low ligand leakage: Comparable to leading resins on the market, ensuring reliable downstream results.

For the customer this means high productivity and scalability - delivering consistently high purity and yield.

The resin is available in bulk and a wide range of convenient prepacked GoBio™ column formats-from small-scale screening to production-scale purification-making it an attractive solution for both process development and commercial manufacturing.

Strong Market Response

Since its introduction, WorkBeads affimAb Edge has already attracted significant attention from the global biopharmaceutical community, with many large biopharma companies actively requesting samples for evaluation. This reflects the industry's need for cost-effective and high-performing alternatives in antibody purification workflows.

"WorkBeads affimAb Edge represents an important step forward in delivering performance, robustness, and process economy to our customers in biopharma. We are proud to see strong demand from leading global companies so early after launch, which reinforces the market's confidence in our technology," said Lone Carlbom, CEO, Bio-Works Technologies AB.